The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced (F3) fibrosis.

This study is comparing two approaches for monitoring and addressing symptoms among adult patients with kidney failure who are treated with hemodialysis. For the first approach patients use an electronic system twice a month to report their symptoms. The system sends alerts to their medical team at the dialysis clinic about the reported symptoms and gives suggestions about how to manage them. The system also provides reports that show patients and their medical team the reported symptoms over time. For the second approach patients complete a quality of life questionnaire that includes questions about symptoms once a year. The questionnaire does not have follow-up support like alerts, symptom management guidance, or reports. In addition, researchers will talk to patients, dialysis clinic personnel, and medical providers about their experiences using the electronic symptom monitoring system to learn about how to best use patient-reported outcome measures in dialysis care.

This study is comparing two different ways Mycophenolate Mofetil (MMF) can be prescribed to pediatric lupus nephritis patients. One way is to prescribe a dose based on body surface area, and the other is to determine the dose base on information from blood samples. The goal is to see if one method works better at reaching the optimal amount of medication levels in the body in order to treat LN most effectively.

Comparing effects of a drug called ziltivekimab versus a placebo on heart disease and chronic kidney disease.

This project will focus on identifying and addressing socio-economic barriers to healthcare (e.g., education, transportation/access) for patients with Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). This pilot program aims to expand supportive services and education to mitigate healthcare barriers, by: 1) enhancing access to tangible transportation support systems to improve healthcare access; and 2) utilizing Pharmacist Counseling and Patient Educational Materials to increase awareness and knowledge of the importance of early diagnosis and treatment, medication adherence, and routine screenings (e.g., urine protein creatinine ratio and urinalysis) for improved health outcomes.